Advertisement
Table 1 The demographic and oncological characteristics
| Patient characteristics | Arm A (cisplatin 100 mg/m2) | Arm B (cisplatin 40 mg/m2) | p |
|---|---|---|---|
| N = 26 | N = 24 | ||
| Gender | |||
| Male | 25 (96.2%) | 23 (95.8%) | 1.000 |
| Female | 1 (3.8%) | 1 (4.2%) | |
| Age (years old) | |||
| Mean (range) | 49.2 (33–63) | 49.0 (32–65) | 0.941 |
| pT | |||
| pT1/2 | 14 (53.8%) | 11 (45.8%) | 0.778 |
| pT3/4 | 12 (46.2%) | 13 (54.2%) | |
| pN | |||
| pN0 | 0 (0%) | 2 (8.3%) | |
| pN1 | 5 (19.2%) | 8 (33.3%) | |
| pN2 | 21 (80.8%) | 14 (58.3%) | |
| Stage | |||
| Stage II | 0 (0%) | 1 (4.2%) | |
| Stage III | 3 (11.5%) | 4 (16.7%) | |
| Stage IV | 23 (88.5%) | 19 (79.2%) | |
| Differentiation | |||
| Well | 7 (26.9%) | 5 (20.8%) | |
| Moderate | 15 (57.7%) | 17 (70.8%) | |
| Poor | 4 (15.4%) | 2 (8.3%) | |
| Primary Site | |||
| Buccal | 10 (38.5%) | 9 (37.5%) | |
| Tongue | 10 (38.5%) | 11 (45.8%) | |
| Gum | 5 (19.2%) | 3 (12.5%) | |
| Others | 1 (3.8%) | 1 (4.2%) | |
| ECS | |||
| No | 5 (19.2%) | 9 (37.5%) | 0.211 |
| Yes | 21 (80.8%) | 15 (62.5%) | |
| Margin | |||
| Negative | 25 (96.2%) | 20 (83.3%) | 0.182 |
| Positive | 1 (3.8%) | 4 (16.7%) | |
| Tumor size (mm) | |||
| Mean (range) | 31.19 (12–68) | 34.13 (12–60) | 0.414 |
